Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels >20 ng/mL

Article ID	Journal	Published Year	Pages	File Type
9872067	International Journal of Radiation OncologyBiologyPhysics	2005	7 Pages	PDF

Abstract

Conclusions: Several randomized trials have demonstrated the benefit of LT-AD in high-risk patients with prostate cancer. In some reports, the survival advantage seems to be restricted to patients with high Gleason score. The present analysis supports the hypothesis that LT-AD improves bNED and survival rates in patients presenting with a PSA level >20, irrespective of Gleason score or T stage.

Keywords

androgen deprivation therapy Prostate radiotherapy Prostate cancer Biochemical outcome prostate-specific antigen

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels >20 ng/mL

Authors

Eric (F.R.C.P.C.), Tom (F.R.C.P.C.), Kenny Won Jae M.Sc., Mitchell (F.R.C.P.C.), Pauline T. (F.R.C.P.C.), Prostate Cancer Outcomes Initiative Prostate Cancer Outcomes Initiative,